AMSA Pharm-free Scorecard 2010
B University of Missouri-Columbia School of Medicine
City: Columbia State: MO

Summary: University of Missouri-Columbia School of Medicine's policies are broadly applicable to the medical school "workforce" (all faculty, students, residents, etc.). This institution has focused on thorough disclosure processes and restricting industry representative conduct. This institution has not provided information on conflicts of interest and drug industry marketing's place in its curriculum, but is ahead of the curve in that it requires institutional approval for workforce members to receive funding for attendance at off-site educational conferences.

Demographics: All medical students train in the University Hospital, University Clinics, and the Women's and Children's Hospital, all part of the University of Missouri Health System. In addition, many students are trained at Ellis Fischel Cancer Center (part of the UM System) and the Harry S. Truman Memorial Veterns Hospital. The submitted policies apply to University Hospital, University Clinics, Women's and Children's Hospital, and Ellis Fischel Cancer Center.

Updates: This institution provided an updated vendor access policy for the 2012-3 AMSA PharmFree Scorecard. Their grade remains a B.


This institution has not granted permission for the posting of their policies on this website for illustrative purposes.

This institution's evaluation was last updated: 4/9/2013.

Gifts & Meals 2 The institution puts a $5 per item limit and a $75 annual limit on gifts per vendor and per workforce member.  It also cites AMA recommendations on gifts.
Consulting relationships 3 Prior approval from Dean for consulting relationships is required.
Industry-funded speaking relationships 2 Compensation for speaking services provided on personal time must be reasonable, and lecture content should be determined by the speaker, not industry sponsors.
Disclosure 2 The completion of an Outside Interest Report is required of those who have real or the appearance of a financial conflict of interest for the University although it is not clear if the document to be filled out is required annually or as needed. The SOM has a separate annual disclosure required for all workforce members.
Pharmaceutical samples 2 The policy limits the distributing of samples to physicians, but not allowing for all medications requiring a prescription to be distributed to physicians, while allowing for over-the-counter medications to be distributed to physicians. Currently, no restrictions/programs on the distribution to patients, besides that all prescription medication samples must be distributed from a pharmacy when present.
Purchasing & Formularies 2 Disclosure of potential conflicts to the committee is required.
Industry Sales Representatives 2 The institution requires industry representatives to complete an orientation/code of conduct in-service before meeting with staff and categorizing them as "Non-Clinical" or "Clinical" representatives. All representatives are required to have scheduled appointments with staff and there are significant restrictions placed on their activities on campus.
On-campus Education 2 Industry funds must pass through an institutional gift account. Educational content is then limited by institutional policy, and financial support for CME events must be fully disclosed. 
Attendance at Industry-Sponsored Lectures & Meetings Off-Campus 3 Individuals may not be compensated for event attendance. Approval is required for travel support.
Industry Support for Scholarships & Funds for Trainees 3 Institutional policy prevents industry from selecting the recipient of funding and scholarships. 
Medical school curriculum 3 The supplied presentation clearly describes issues surrounding pharmaceutical marketing and the influence pharmaceutical and medical device representatives may have on prescribing habits.
Do the policies specify an oversight mechanism? Yes The Compliance Review Committee is cited as the responsible party to review disclosed conflicts of interest and make determinations on necessary corrective actions.
Are there explicit sanctions for noncompliance? No Sanctions not referenced.
What the results mean...
3Model policy
2Good progress toward model policy
1No policy, or policy unlikely to have a substantial effect on behavior
0Did not report
N/APolicy not relevant to this institution (e.g., does not make purchasing decisions)